Table 1.
Demographic and clinical characteristics of the discovery and validation sample used in the study.
| Discovery | Validation | Validation vs. discovery | |||||||
|---|---|---|---|---|---|---|---|---|---|
| ROP vs. HC | ROP vs. HC | ROP (val) vs. ROP (disc) | |||||||
| ROP (N = 108) | HC (N = 195) | t/X² | p | ROP (N = 53) | t/X² | p | t | p | |
| Demographics | |||||||||
| Age | 24.91 (5.11) | 25.32 (6.23) | −0.63 | 0.53 | 25.74 (6.39) | 0.42 | 0.68 | 0.82 | 0.41 |
| Sitea | 39/20/28/8/13 | 48/39/60/35/13 | 11.62 | 0.02* | 53/0/0/0/0 | 98.1 | <0.001*** | 59.26 | <0.001*** |
| Sexa | Female = 35 | Female = 121 | 23.28 | <0.001*** | Female = 21 | 7.67 | 0.01* | 0.53 | 0.47 |
| Years of education | 14.08 (3.3) | 16.02 (3.43) | −4.83 | <0.001*** | 14.05 (3.54) | −3.62 | <0.001*** | −0.06 | 0.96 |
| Illness duration in days | 181.51 (187.46) | – | – | – | 186.38 (203.88) | – | – | −0.15 | 0.88 |
| Chlorpromazine equivalentb | 388.18 (1020.61) | – | – | – | 1208.09 (5205.17) | −1.06 | 0.29 | ||
| Premorbid intelligence | |||||||||
| WAIS (Vocabulary) | 9.89 (3.64) | 12.11 (2.85) | −5.48 | <0.001*** | 9.22 (3.3) | −5.61 | <0.001*** | −1.13 | 0.26 |
| WAIS (Matrices) | 9.35 (2.7) | 11.23 (2.25) | −6.14 | <0.001*** | 10.35 (2.73) | −2.15 | 0.03* | 2.16 | 0.03* |
| GAF (symptoms) | |||||||||
| Lifetime | 77.77 (10.09) | 88.48 (5.63) | −10.15 | <0.001*** | 77.22 (8.79) | −8.61 | <0.001*** | −0.35 | 0.73 |
| Past year | 59.12 (15.79) | 87.43 (6.1) | −17.83 | <0.001*** | 62.3 (14.19) | −12.24 | <0.001*** | 1.26 | 0.21 |
| Past month | 41.85 (13.52) | 86.98 (6.48) | −32.54 | <0.001*** | 39.86 (13.02) | −24.81 | <0.001*** | −0.88 | 0.38 |
| GAF (disability) | |||||||||
| Lifetime | 77.11 (8.99) | 86.84 (5.21) | −10.29 | <0.001*** | 75.78 (9.74) | −7.75 | <0.001*** | −0.82 | 0.42 |
| Past year | 61.36 (13.66) | 85.95 (5.82) | −17.76 | <0.001*** | 61.82 (14.21) | −11.76 | <0.001*** | 0.19 | 0.85 |
| Past month | 45.39 (12.24) | 85.51 (6.16) | −31.78 | <0.001*** | 42.8 (11.77) | −24.8 | <0.001*** | −1.27 | 0.21 |
| PANSS | |||||||||
| Positive scale | 18.07 (6.43) | – | – | – | 20.27 (4.72) | – | – | −2.39 | 0.02* |
| Negative scale | 16.75 (8.11) | – | – | – | 15.33 (6.21) | – | – | 1.2 | 0.23 |
| General scale | 36.05 (10.6) | – | – | – | 34.02 (10.02) | – | – | 1.15 | 0.25 |
| BDI score | 20.91 (11.41) | 2.80 (4.73) | −14.91 | <0.001*** | 22.44 (12.79) | −10.14 | <0.001*** | −0.69 | 0.49 |
ROP recent onset psychosis, HC healthy control, WAIS Wechsler Adult Intelligence Scale, GAF General Assessment of Functioning, PANSS Positive and Negative Syndrome Scale, BDI Beck Depression Inventory.
aChi-squared test.
bCumulative sum of Chlorpromazine equivalents divided by number of days treated.
*p < 0.05, ***p < 0.001.